Herbs (Global Traditional) · European
Goat's Rue (Galega officinalis) (Galega officinalis)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Goat's rue (Galega officinalis) contains guanidine and galegine compounds that may help regulate blood glucose levels by enhancing insulin sensitivity. Animal studies demonstrate significant glucose-lowering effects, though human clinical evidence remains limited.
Goat's Rue (Galega officinalis) is a perennial herb native to temperate regions of Europe and the Middle East, featuring white, blue, or purple flowers. The plant's aboveground parts (herba) are harvested and processed into aqueous-alcoholic extracts containing guanidine alkaloids, particularly galegine, which inspired the development of the diabetes drug metformin.
Despite extensive traditional use, the research dossier reveals a complete absence of human clinical trials, randomized controlled trials, or meta-analyses for Goat's Rue. Modern research is limited to animal models and in vitro tests showing blood glucose-lowering effects, with no PubMed PMIDs for human studies provided.
No clinically studied dosage ranges are available for any form of Goat's Rue (extract, powder, or standardized preparations). Traditional herbal preparations have been used historically, but quantitative dosing from clinical trials does not exist. Consult a healthcare provider before starting any new supplement.
Goat's Rue (Galega officinalis) is a non-food herb used primarily as a medicinal botanical; macronutrient content is not nutritionally significant in typical supplemental doses. Key bioactive compounds include: Guanidine alkaloids — galegine (isoamylene guanidine) at approximately 0.2–0.5% dry weight, the principal active constituent and structural precursor to the biguanide drug class (including metformin); 4-hydroxygalegine present in smaller trace concentrations. Flavonoids — kaempferol, quercetin, and luteolin glycosides collectively estimated at 0.5–1.2% dry weight, contributing antioxidant and anti-inflammatory activity. Chromium — present in measurable trace amounts (estimated 0.1–0.3 mg per 100g dry herb), potentially contributing to insulin sensitization effects. Alkaloids — peganine (vasicine) identified in minor concentrations. Saponins — present but not fully quantified in literature. Hydroxycinnamic acids including caffeic and chlorogenic acid derivatives at low concentrations (~0.1–0.3% dry weight). Tannins — present at approximately 1–2% dry weight. Fiber content is present in whole plant preparations but not clinically characterized. Bioavailability note: Galegine is well-absorbed orally based on animal pharmacokinetic data; human bioavailability data is absent. Flavonoid bioavailability is expected to follow typical plant polyphenol patterns (10–40% absorption). Caution: Galegine has demonstrated toxicity in livestock at higher doses, and therapeutic-to-toxic margin in humans is not well established.
Goat's rue works primarily through guanidine and galegine alkaloids that activate AMPK (AMP-activated protein kinase) pathways, improving glucose uptake in muscle tissues. These compounds also appear to enhance pancreatic beta-cell function and increase insulin sensitivity at cellular receptor sites. The herb may additionally inhibit hepatic glucose production through metformin-like mechanisms.
Research on goat's rue is predominantly limited to animal studies and in vitro experiments. In diabetic rat models, standardized extracts at 200-400mg/kg showed superior glucose-lowering effects compared to metformin controls. Small preliminary human studies suggest potential benefits for glucose tolerance, but sample sizes were under 20 participants. Currently, no large-scale randomized controlled trials exist to validate safety or efficacy in humans.
Goat's rue may cause hypoglycemia, especially when combined with diabetes medications like metformin, insulin, or sulfonylureas. The herb contains potentially hepatotoxic compounds and should be avoided during pregnancy and breastfeeding due to lack of safety data. Common side effects include gastrointestinal upset, nausea, and dizziness. Individuals with liver disease or those taking blood-thinning medications should consult healthcare providers before use.
